<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03803111</url>
  </required_header>
  <id_info>
    <org_study_id>BIHKF-7162</org_study_id>
    <nct_id>NCT03803111</nct_id>
  </id_info>
  <brief_title>Effects of Iron Therapy and Exercise Training in Patients With Heart Failure and Iron Deficiency</brief_title>
  <acronym>IronEx</acronym>
  <official_title>A Randomized Trial on Sequential Effects of Iron Therapy and Exercise Training in Patients With Heart Failure and Iron Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Herzzentrum Bremen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Herzzentrum Bremen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is the aim of the study to prove, if intravenous supplementation with ferric
      carboxymaltose in iron-deficient patients with heart failure with reduced ejection fraction
      (HFrEF) leads to better exercise training effects compared to exercise training without
      previous iron supplementation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In patients with heart failure with reduced ejection fraction (HFrEF) exercise training (ET)
      is recommended. In iron-deficient HFrEF patients iron supplementation by ferric
      carboxymaltose (FCM) is recommended. Both treatment options (ET and iron supplementation)
      affect oxidative metabolism.

      In this study iron-deficient HFrEF patients are included and randomly assigned to two study
      arms:

      Study arm A: Intravenous iron supplementation with FCM, subsequent (after 2 months) ET
      program.

      Study arm B: ET program, subsequent (after 2 months) intravenous iron supplementation with
      FCM.

      Primary study endpoint is exercise capacity (Peak VO2). Secondary endpoints are 6-minute
      walking distance, NYHA class, echocardiographic parameters and the combined endpoint
      cardiovascular hospitalizations and death.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Exercise capacity (Peak VO2)</measure>
    <time_frame>Change from baseline to 4 months</time_frame>
    <description>Peak VO2 is measured by spiroergometry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>6 Minute walking distance</measure>
    <time_frame>Change from baseline to 4 months</time_frame>
    <description>To further assess exercise capacity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New York Heart Association class (class I, II, III, IV with class I = best status, and class IV = worst status)</measure>
    <time_frame>Improvement or deterioration of NYHA class from baseline to 4 months</time_frame>
    <description>To assess symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic ejection fraction of left ventricular function (measured in %, the lower the worse)</measure>
    <time_frame>Improvement or deterioration of ejection fraction from baseline to 4 months</time_frame>
    <description>Systolic and diastolic function, chamber diameters, strain analyses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Combined endpoint cardiovascular hospitalizations and death</measure>
    <time_frame>After 2 and 4 months</time_frame>
    <description>To assess major events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Heart Failure With Reduced Ejection Fraction</condition>
  <condition>Exercise Training</condition>
  <condition>Ferric Carboxymaltose</condition>
  <arm_group>
    <arm_group_label>Initial FCM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous iron supplementation with FCM, subsequent (after 2 months) exercise training program</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Initial exercise</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Exercise training program, subsequent (after 2 months) intravenous iron supplementation with FCM</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Initial exercise training</intervention_name>
    <description>Initial exercise training program</description>
    <arm_group_label>Initial exercise</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Initial FCM</intervention_name>
    <description>Initial intravenous iron supplementation (FCM)</description>
    <arm_group_label>Initial FCM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Subsequent FCM</intervention_name>
    <description>Subsequent intravenous iron Supplementation (FCM) after 2 months</description>
    <arm_group_label>Initial exercise</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Subsequent exercise training</intervention_name>
    <description>Subsequent exercise training program after 2 months</description>
    <arm_group_label>Initial FCM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Heart failure with reduced ejection fraction â‰¤ 40%

          -  New York Heart Failure Asssociation class II-III

          -  Iron deficiency (ferritin &lt; 100 ng/ml or 100-299 ng/ml, if transferrin saturation &lt;
             20%)

        Exclusion Criteria:

          -  Planned cardiovascular interventions (such as bypass surgery or valve interventions)

          -  Acute coronary Syndrome

          -  Malignant rhythm disturbances

          -  Acute or chronic infection

          -  Reduced prognosis or exercise capacity by non-cardiac comorbidities

          -  Missing informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>January 8, 2019</study_first_submitted>
  <study_first_submitted_qc>January 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 14, 2019</study_first_posted>
  <last_update_submitted>February 14, 2020</last_update_submitted>
  <last_update_submitted_qc>February 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Herzzentrum Bremen</investigator_affiliation>
    <investigator_full_name>Dr. Harm Wienbergen</investigator_full_name>
    <investigator_title>Head of the Bremen Institute for Heart and Circulation Research (BIHKF)</investigator_title>
  </responsible_party>
  <keyword>Heart Failure with Reduced Ejection Fraction</keyword>
  <keyword>Exercise Training Program</keyword>
  <keyword>Iron Deficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

